Literature DB >> 10898132

Management of brain abscesses with sequential intravenous/oral antibiotic therapy.

A T Skoutelis1, C A Gogos, T E Maraziotis, H P Bassaris.   

Abstract

Eight patients with brain abscesses who refused prolonged hospitalisation were treated with a short course (6-12 days) of intravenous antibiotics followed by prolonged treatment (15-19 weeks) with an oral antibiotic regimen consisting of metronidazole, ciprofloxacin and amoxicillin. All patients responded favourably as shown clinically and in imaging studies. No severe adverse events or sequelae were noted. On admission all patients had a normal or mildly impaired mental status, abscesses less than 3 cm in diameter and no serious predisposing factors. Although combined surgical/medical treatment remains the standard approach in management of these patients, the findings suggest that oral antibiotic therapy only subsequent to a short course of intravenous antibiotics may be an acceptable alternative in selected cases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10898132     DOI: 10.1007/s100960050489

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  3 in total

1.  Efficacy and safety of cefotaxime in combination with metronidazole for empirical treatment of brain abscess in clinical practice: a retrospective study of 66 consecutive cases.

Authors:  A-K Jansson; P Enblad; J Sjölin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-12-11       Impact factor: 3.267

2.  Pediatric focal intracranial suppuration: a UK single-center experience.

Authors:  Theresa S Cole; Marcia E Clark; Alistair J Jenkins; Julia E Clark
Journal:  Childs Nerv Syst       Date:  2012-08-05       Impact factor: 1.475

3.  Sequential Intravenous-Oral Therapy for Pediatric Streptococcus anginosus Intracranial Infections.

Authors:  Daniel S Dodson; Heather R Heizer; James T Gaensbauer
Journal:  Open Forum Infect Dis       Date:  2022-01-06       Impact factor: 3.835

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.